Covid 19 may be helpful

Previous topic - Next topic

0 Members and 1 Guest are viewing this topic.

Jack1909

Looking at the bright side, from our specific point of view, my brother is a covid doctor in Berlin and he told me many ex covid patients already dismissed are getting back at his office complaining breathing issues, some in a middle of respiratory crisis. They may have fibrosis in the lungs and the research for antifibrotic drugs speed up.  
31 yrs old
Severe congenital curvature. 3 straightening surgeries
Big lump/stitch w/ left deviation after 2012 surgery
Severe ED after last one in 2014. Still crooked
Slightly improved w/ shockwave therapy
Looks like only one side of my penis works

hope794

26 yo from Italy.
Peyronie's since abt 2014
Abt 20-25° bend, w/ a moderate twist to the left
ED for 4 years and getting worse
From pornstar-like to moderately depressed - still fighting for a solution.

Patientxyz1992

Hate to be pessimistic but equally possible to stuck with dick fibrosis + lung fibrosis till the rest of life...
29 years old with injury induced Peyronies Disease - 7 years ago
Straight erections but easy to lose and hard to fill with soft glans
No morning erections
been depressed but not anymore
The biggest problem with my Peyronies Disease is loss of sexual desire.

skunkworks

More time for traction if you're working from home!
This is an emotionally destructive condition, we all have it, let's be nice to each other.

Review of current treatment options by Levine and Sherer]

Hontas

I am pretty sure it will be made impossible for you to buy a certain drug even if it works perfectly on lungs. With the current agenda of world politics where limp dick leaders want to cut every other men's penis off, i doubt we will ever have an actual solution.

To add to this, i don't think they are connected at all. I probably already had a COVID infection which was the most laughable illness i had. I legit only coughed for two days and then recovered. This disease is only lethal in high doses. Which means it is nothing like Peyronie's or connective tissue fibrosis in particular. This is rather an immune system shutdown/cytokine storm related due to HIGH viral load, not due to the virus itself.

Sorry for all the negativity, but i hate to see people full of unrealistic expectations, i also do hope to live a good and fulfilling life as much as you guys but we have to be smarter about it. All the power to the people working this site inside out. I haven't been able to be here due to personal reasons but am on a close lookout for progress.

This can't even possibly be solved by one billionaire so it's good to have woke people and masses that will actually pressure medical community into finding actual solutions for this connective tissue disease. They won't just fix our dicks from kindness of their hearts. I am sorry but this is the reality.

CrookedJohnson


June 08, 2020 07:00 ET | Source: FibroGen, Inc
SAN FRANCISCO, June 08, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the initiation of an open-label, randomized, parallel-arm study investigating the efficacy and safety of pamrevlumab versus standard of care in patients with severe coronavirus 2019 (COVID-19) infection. The trial is being conducted by Professor Luca Richeldi, M.D., Ph.D., Head of the Division of Pulmonary Medicine at Fondazione Policlinico Universitario A. Gemelli IRCCS, and Professor of Respiratory Medicine at Catholic University of the Sacred Heart in Rome, Italy.

BOREA is a Phase 2/3 investigator-initiated clinical trial investigating the efficacy and safety of pamrevlumab in approximately 68 patients hospitalized with COVID-19. The primary objective of this study is to assess the effect of pamrevlumab on blood oxygenation in patients with COVID-19 infection. Patients will be randomized to treatment with pamrevlumab or standard of care in a 1:1 ratio. Based on the investigator's decision, a subgroup of patients may continue treatment for up to 12 weeks.

"Recent data indicate the presence of interstitial pneumonia in the majority of hospitalized patients infected with COVID-19. The interstitial pneumonia is usually bilateral and leads to decreased blood oxygen levels, respiratory failure, intubation, and, ultimately, death in a significant proportion of patients who require mechanical ventilation," said Elias Kouchakji, M.D., Senior Vice President, Clinical Development, Drug Safety, and Pharmacovigilance, FibroGen. "Connective tissue growth factor (CTGF) may promote vascular leakage and lead to pulmonary edema. Administration of pamrevlumab, an anti-CTGF monoclonal antibody, may reverse this edema, and thus improve oxygenation in patients with COVID-19-induced pneumonia."

Pamrevlumab is a first-in-class antibody developed by FibroGen to inhibit the activity of CTGF, a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. This trial will assess pamrevlumab's effect on patient time to and on ventilatory support, currently the most urgent need, and its potential to reduce mortality and fibrotic sequelae in the lung.
If you want answers, Please help us by filling in your signature block

Click here for Directions